Webinar
Presented on: September 22, 2026
Platform trials that test several therapies for rare childhood cancers under one protocol hold great promise. Their progress depends on academic-industry partnerships, which have historically stalled over asset access, regulatory alignment, contracts, and funding. This webinar launched the Childhood Cancer Academic-Industry Collaborative Platform Trials (C3PT) Blueprint and accompanying Tools. The MRCT Center co-developed it with Innovative Therapies for Children and Adolescents with Cancer (ITCC), Blood Cancer United, and the Children’s Oncology Group (COG). It pairs a Position Narrative with ten tools.
PRESENTER/MODERATOR: Pamela Kearns, OBE, PhD, FRCPCH Emeritus, Professor of Clinical Paediatric Oncology at the University of Birmingham; who co-led the C3PT effort with the MRCT Center
PANELISTS:
Patient advocates:
Amanda Monteiro, parent advocate, palliative care social worker, and member of the Glo-BNHL Trial Steering Committee;
Nicole Scobie, Chair of ACCELERATE and president-emeritus of Zoé4life
Regulators:
Dominik Karres, Senior Scientific Officer, Paediatric Medicines Office, European Medicines Agency;
Martha Donoghue, Associate Director for Pediatric Oncology and Rare Cancers, FDA Oncology Center of Excellence
Industry:
George Kirk, VP Global Franchise Head and lead of the Paediatric Oncology Development Team, AstraZeneca;
Kerri Nottage, Senior Director, Pediatric Drug Development, Johnson & Johnson
Academia:
Amos Burke, Professor of Paediatric Oncology and Director of the Cancer Research UK Clinical Trials Unit, University of Birmingham, and Glo-BNHL Chief Investigator;
Elizabeth Fox, St. Jude Children’s Research Hospital, and Chair of Developmental Therapeutics, Children’s Oncology Group